STOCK TITAN

[Form 4] Vir Biotechnology, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Vir Biotechnology (VIR): insider transaction SVF Endurance (Cayman) Limited, affiliated with SoftBank Vision Fund, reported open‑market sales made pursuant to a Rule 10b5‑1 trading plan entered into on September 3, 2025.

It sold 144,266 shares on October 22, 2025 at a weighted average price of $6.1529, and 154,383 shares on October 23, 2025 at a weighted average price of $5.9898. After these transactions, the reporting person disclosed beneficial ownership of 14,711,635 shares, held indirectly.

Vir Biotechnology (VIR): operazione di insider SVF Endurance (Cayman) Limited, affiliata a SoftBank Vision Fund, ha riferito vendite sul mercato aperto effettuate secondo un piano di negoziazione Rule 10b5-1 stipulato il 3 settembre 2025.

Ha venduto 144.266 azioni il 22 ottobre 2025 a un prezzo medio ponderato di 6,1529 dollari e 154.383 azioni il 23 ottobre 2025 a un prezzo medio ponderato di 5,9898 dollari. Dopo queste transazioni, la persona che segnala ha dichiarato una partecipazione di titolarità di 14.711.635 azioni, detenute indirettamente.

Vir Biotechnology (VIR): operación de insider SVF Endurance (Cayman) Limited, afiliada a SoftBank Vision Fund, reportó ventas en el mercado abierto realizadas conforme a un plan de negociación Rule 10b5-1 suscrito el 3 de septiembre de 2025.

Vendió 144,266 acciones el 22 de octubre de 2025 a un precio medio ponderado de 6.1529 dólares y 154,383 acciones el 23 de octubre de 2025 a un precio medio ponderado de 5.9898 dólares. Después de estas transacciones, la persona informante declaró la titularidad beneficiosa de 14,711,635 acciones, poseídas indirectamente.

Vir Biotechnology (VIR): 내부자 거래 SVF Endurance (Cayman) Limited는 SoftBank Vision Fund와 계열된 회사로, 2025년 9월 3일에 체결된 Rule 10b5-1 거래 계획에 따라 공개시장 매도를 보고했습니다.

2025년 10월 22일에 가중평균가 6.1529달러로 144,266주, 2025년 10월 23일에 가중평균가 5.9898달러로 154,383주를 매도했습니다. 이러한 거래 이후, 보고자는 간접적으로 보유한 주식 14,711,635주를 유익하게 소유하고 있음을 공시했습니다.

Vir Biotechnology (VIR) : opération d'initié SVF Endurance (Cayman) Limited, affiliée à SoftBank Vision Fund, a déclaré des ventes sur le marché libre effectuées conformément à un plan de négociation Rule 10b5-1 conclu le 3 septembre 2025.

Elle a vendu 144 266 actions le 22 octobre 2025 à un prix moyen pondéré de 6,1529 dollars et 154 383 actions le 23 octobre 2025 à un prix moyen pondéré de 5,9898 dollars. Après ces transactions, la personne déclarant a déclaré une propriété bénéficiaire de 14 711 635 actions, détenues indirectement.

Vir Biotechnology (VIR): Insider-Transaktion SVF Endurance (Cayman) Limited, mit SoftBank Vision Fund verbunden, meldete Offenmarktverkäufe, die gemäß einem Rule 10b5-1-Handelsplan getätigt wurden, der am 3. September 2025 abgeschlossen wurde.

Sie verkauften 144.266 Aktien am 22. Oktober 2025 zu einem gewichteten Durchschnittspreis von 6,1529 USD und 154.383 Aktien am 23. Oktober 2025 zu einem gewichteten Durchschnittspreis von 5,9898 USD. Nach diesen Transaktionen legte die meldende Person eine nutzbringende Eigentümerschaft an 14.711.635 Aktien vor, die indirekt gehalten werden.

فير بيوتيكالوجي (VIR): تصرّف داخلي SVF Endurance (Cayman) Limited، المرتبطة بـ SoftBank Vision Fund، ذكرت صفقات سوق مفتوح تمت بموجب خطة تداول Rule 10b5-1 الموقعة في 3 سبتمبر 2025.

باع 144,266 سهماً في 22 أكتوبر 2025 بسعر متوسط وزني قدره 6.1529 دولار، و154,383 سهماً في 23 أكتوبر 2025 بسعر متوسط وزني قدره 5.9898 دولار. بعد هذه المعاملات، أعلن الشخص المبلغ عن الملكية المفيدة لـ14,711,635 سهماً، مملوكة بشكل غير مباشر.

Positive
  • None.
Negative
  • None.

Insights

Analyzing...

Vir Biotechnology (VIR): operazione di insider SVF Endurance (Cayman) Limited, affiliata a SoftBank Vision Fund, ha riferito vendite sul mercato aperto effettuate secondo un piano di negoziazione Rule 10b5-1 stipulato il 3 settembre 2025.

Ha venduto 144.266 azioni il 22 ottobre 2025 a un prezzo medio ponderato di 6,1529 dollari e 154.383 azioni il 23 ottobre 2025 a un prezzo medio ponderato di 5,9898 dollari. Dopo queste transazioni, la persona che segnala ha dichiarato una partecipazione di titolarità di 14.711.635 azioni, detenute indirettamente.

Vir Biotechnology (VIR): operación de insider SVF Endurance (Cayman) Limited, afiliada a SoftBank Vision Fund, reportó ventas en el mercado abierto realizadas conforme a un plan de negociación Rule 10b5-1 suscrito el 3 de septiembre de 2025.

Vendió 144,266 acciones el 22 de octubre de 2025 a un precio medio ponderado de 6.1529 dólares y 154,383 acciones el 23 de octubre de 2025 a un precio medio ponderado de 5.9898 dólares. Después de estas transacciones, la persona informante declaró la titularidad beneficiosa de 14,711,635 acciones, poseídas indirectamente.

Vir Biotechnology (VIR): 내부자 거래 SVF Endurance (Cayman) Limited는 SoftBank Vision Fund와 계열된 회사로, 2025년 9월 3일에 체결된 Rule 10b5-1 거래 계획에 따라 공개시장 매도를 보고했습니다.

2025년 10월 22일에 가중평균가 6.1529달러로 144,266주, 2025년 10월 23일에 가중평균가 5.9898달러로 154,383주를 매도했습니다. 이러한 거래 이후, 보고자는 간접적으로 보유한 주식 14,711,635주를 유익하게 소유하고 있음을 공시했습니다.

Vir Biotechnology (VIR) : opération d'initié SVF Endurance (Cayman) Limited, affiliée à SoftBank Vision Fund, a déclaré des ventes sur le marché libre effectuées conformément à un plan de négociation Rule 10b5-1 conclu le 3 septembre 2025.

Elle a vendu 144 266 actions le 22 octobre 2025 à un prix moyen pondéré de 6,1529 dollars et 154 383 actions le 23 octobre 2025 à un prix moyen pondéré de 5,9898 dollars. Après ces transactions, la personne déclarant a déclaré une propriété bénéficiaire de 14 711 635 actions, détenues indirectement.

Vir Biotechnology (VIR): Insider-Transaktion SVF Endurance (Cayman) Limited, mit SoftBank Vision Fund verbunden, meldete Offenmarktverkäufe, die gemäß einem Rule 10b5-1-Handelsplan getätigt wurden, der am 3. September 2025 abgeschlossen wurde.

Sie verkauften 144.266 Aktien am 22. Oktober 2025 zu einem gewichteten Durchschnittspreis von 6,1529 USD und 154.383 Aktien am 23. Oktober 2025 zu einem gewichteten Durchschnittspreis von 5,9898 USD. Nach diesen Transaktionen legte die meldende Person eine nutzbringende Eigentümerschaft an 14.711.635 Aktien vor, die indirekt gehalten werden.

فير بيوتيكالوجي (VIR): تصرّف داخلي SVF Endurance (Cayman) Limited، المرتبطة بـ SoftBank Vision Fund، ذكرت صفقات سوق مفتوح تمت بموجب خطة تداول Rule 10b5-1 الموقعة في 3 سبتمبر 2025.

باع 144,266 سهماً في 22 أكتوبر 2025 بسعر متوسط وزني قدره 6.1529 دولار، و154,383 سهماً في 23 أكتوبر 2025 بسعر متوسط وزني قدره 5.9898 دولار. بعد هذه المعاملات، أعلن الشخص المبلغ عن الملكية المفيدة لـ14,711,635 سهماً، مملوكة بشكل غير مباشر.

Vir Biotechnology (VIR): 内幕交易 SVF Endurance (Cayman) Limited,隶属于 SoftBank Vision Fund,报告了根据于 2025 年 9 月 3 日签订的 Rule 10b5-1 交易计划进行的场外市场销售。

2025 年 10 月 22 日以加权平均价格 6.1529 美元出售了 144,266 股,2025 年 10 月 23 日以加权平均价格 5.9898 美元出售了 154,383 股。经这些交易后,报告人披露间接持有 14,711,635 股的受益所有权。

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SVF Endurance (Cayman) Ltd

(Last) (First) (Middle)
C/O WALKERS CORP LTD., 190 ELGIN AVENUE

(Street)
GEORGE TOWN E9 KY1-9008

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/22/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/22/2025 S(1) 144,266 D $6.1529(2) 14,866,018 I See footnote(3)
Common Stock 10/23/2025 S(1) 154,383 D $5.9898(4) 14,711,635 I See footnote(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
SVF Endurance (Cayman) Ltd

(Last) (First) (Middle)
C/O WALKERS CORP LTD., 190 ELGIN AVENUE

(Street)
GEORGE TOWN E9 KY1-9008

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
SOFTBANK VISION FUND (AIV M1) L.P.

(Last) (First) (Middle)
1521 CONCORD PIKE

(Street)
WILMINGTON, DE 19803

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
SB INVESTMENT ADVISERS (UK) LTD

(Last) (First) (Middle)
69 GROSVENOR STREET

(Street)
LONDON, X0 W1K 3JP

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.08 to $6.2552. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.92 to $6.177. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
SVF Endurance (Cayman) Limited, By: /s/ Nilani Perera, Director 10/24/2025
SoftBank Vision Fund (AIV M1) L.P., By: SB Investment Advisers (UK) Limited, its manager, By: /s/ Amanda Sanchez-Barry, General Counsel 10/24/2025
SB Investment Advisers (UK) Limited, By: /s/ Amanda Sanchez-Barry, General Counsel 10/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did VIR report on this Form 4?

SVF Endurance (Cayman) Limited reported open‑market sales of 144,266 shares on October 22, 2025 and 154,383 shares on October 23, 2025.

Were the VIR share sales under a 10b5-1 plan?

Yes. The sales were made pursuant to a Rule 10b5‑1 trading plan entered into on September 3, 2025.

What prices were reported for the VIR share sales?

Weighted average prices were $6.1529 on October 22, 2025 and $5.9898 on October 23, 2025, with trades executed within disclosed price ranges.

How many VIR shares does the reporting person own after the transactions?

The filing lists 14,711,635 shares beneficially owned indirectly after the reported sales.

Who is the reporting person on the VIR Form 4?

The shares are held of record by SVF Endurance (Cayman) Limited, affiliated with SoftBank Vision Fund (AIV M1) L.P. managed by SB Investment Advisers (UK) Limited.

Is the Form 4 filed by more than one reporting person?

Yes. The form indicates it was filed by more than one reporting person.
Vir Biotechnology, Inc.

NASDAQ:VIR

VIR Rankings

VIR Latest News

VIR Latest SEC Filings

VIR Stock Data

802.94M
106.10M
10.49%
81.81%
8.58%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN FRANCISCO